Does Aetna (CVS Health) Cover Fosamax (Alendronate)?

What Is Alendronate (Fosamax) and Why Does Coverage Matter?

Alendronate is the most widely prescribed oral bisphosphonate for osteoporosis in the United States, and its formulary placement directly affects whether patients fill their prescription or abandon it at the pharmacy counter. The FDA approved alendronate sodium (brand: Fosamax) in 1995 for postmenopausal osteoporosis and later extended the label to include male osteoporosis, glucocorticoid-induced osteoporosis, and Paget disease of bone [1]. Generic alendronate has been commercially available since 2008, which is the primary reason most insurers, including Aetna, place the generic on a preferred low-cost tier.

Adherence to bisphosphonate therapy is a well-documented problem. A 2006 analysis in Osteoporosis International found that fewer than 50% of patients remained on oral bisphosphonate therapy at 12 months, and cost was one of the leading modifiable barriers [2]. When a patient's insurer places brand Fosamax on a high tier or imposes step therapy, that administrative friction compounds an already fragile adherence picture.

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) demonstrated that alendronate 5 to 10 mg daily reduced the risk of hip fracture by 51% and vertebral fracture by 47% over 3 years compared with placebo in postmenopausal women with low bone density [3]. Those numbers establish the clinical stakes: an unfilled prescription is not a minor inconvenience. The American Association of Clinical Endocrinologists (AACE) 2020 osteoporosis guidelines list alendronate as a first-line agent for most patients at high fracture risk [4].

How Aetna (CVS Health) Structures Its Drug Formulary

Aetna (CVS Health) operates a tiered formulary system. Understanding which tier a drug occupies tells you your copay range before you reach the pharmacy.

Most Aetna commercial PPO and HMO plans use a four- or five-tier formulary:

• Tier 1: Low-cost preferred generics, typically $0, $15 copay
• Tier 2: Non-preferred generics or lower-cost preferred brands, typically $20, $45 copay
• Tier 3: Preferred brands, typically $45, $75 copay
• Tier 4: Non-preferred brands or specialty-adjacent drugs, typically $75, $120 copay

Generic alendronate (70 mg tablet, 4-count monthly supply) appears on Tier 1 or Tier 2 of most Aetna commercial formularies [5]. Brand Fosamax typically lands on Tier 3 or Tier 4 because generic equivalents exist. The exact tier varies by the specific Aetna plan, employer group, and plan year, so patients must check the Summary of Benefits and Coverage document or use the Aetna drug cost tool at aetna.com with their member ID.

Aetna follows the Academy of Managed Care Pharmacy (AMCP) framework for formulary evidence review. For a drug with a generic available, placement of the brand on a non-preferred tier is standard practice across nearly all commercial managed care formularies [6]. The CVS Health integration since 2018 has also given Aetna access to CVS Caremark pharmacy benefit management data, which the company uses to model utilization patterns when updating formulary tiers annually.

Does Aetna Require Prior Authorization for Alendronate?

Generic alendronate does not require prior authorization on the majority of Aetna commercial plans. Brand-name Fosamax may require prior authorization depending on the plan.

When prior authorization (PA) does apply to brand Fosamax, Aetna's medical necessity criteria typically require the prescriber to document: (1) a confirmed diagnosis of osteoporosis or osteopenia with a T-score at or below -1.0 by DXA scan, (2) the clinical reason the patient cannot use generic alendronate (such as documented intolerance or prior failure), and (3) that the patient meets FDA-labeled indications [7]. The PA difficulty for brand Fosamax is moderate to high because Aetna, like most payers, treats generic availability as a sufficient clinical alternative in the absence of a documented contraindication.

Physicians submitting PA requests for brand Fosamax should include:

• DXA report with T-score values at hip and lumbar spine
• Fracture risk assessment (FRAX score or clinical equivalent)
• Any documented adverse effects from generic formulations
• Current medication list showing no contraindications to bisphosphonates

The 2022 National Osteoporosis Foundation (NOF) Clinician's Guide recommends initiating pharmacotherapy in postmenopausal women with a T-score at or below -2.5, or in those with a T-score between -1.0 and -2.5 whose 10-year FRAX hip fracture probability is at or above 3% [8]. Citing this guideline language directly in the PA request helps frame medical necessity in terms the Aetna clinical reviewer will recognize.

Step Therapy: Does Aetna Require a Generic Trial Before Brand Fosamax?

Step therapy applies to brand Fosamax on many Aetna commercial plans and requires documentation of a prior trial of generic alendronate. This is the most common reason a brand Fosamax claim is rejected at the pharmacy.

Step therapy (sometimes called "fail-first" protocols) requires a patient to try a lower-cost drug before the insurer will cover a more expensive alternative. For brand Fosamax, the required step is usually a 30- to 90-day trial of generic alendronate at the equivalent dose. If the patient has already been on generic alendronate and experienced documented side effects such as esophageal irritation, severe musculoskeletal pain, or atypical femur fracture warning signs, the prescriber can request a step therapy exception by submitting the relevant clinical documentation [9].

Several states have enacted step therapy reform laws that limit how long a payer can require a step therapy trial. As of 2024, 32 states plus the District of Columbia have laws restricting step therapy in at least some plan types [10]. Patients on fully insured Aetna state plans in those jurisdictions may have shorter mandatory step periods or expedited exception pathways. Self-funded employer plans governed by ERISA are exempt from state step therapy laws, so the federal appeals pathway described below applies instead.

The Aetna Appeal Process for a Denied Fosamax Claim

A denial of brand Fosamax by Aetna is not final. Federal law under the Affordable Care Act and ERISA mandates a multi-level appeals process.

Step 1: First-level internal appeal. File within 180 days of the denial notice for most Aetna commercial plans. Submit the appeal in writing with supporting clinical documentation: the prescriber's letter of medical necessity, DXA results, FRAX score, and any records of adverse effects on generic alendronate. Aetna must issue a decision within 30 days for prospective (pre-service) appeals or 60 days for retrospective (post-service) appeals [11].

Step 2: Second-level internal appeal. If the first-level appeal is denied, most Aetna plans allow a second internal review, sometimes by a physician in a relevant specialty. Request that the reviewing physician be board-certified in endocrinology or rheumatology.

Step 3: Independent external review. After exhausting internal appeals, patients on fully insured commercial plans have the right to an independent external review organization (IRO) under state or federal law. The IRO decision is binding on Aetna. Under the ACA, the external review decision must be issued within 45 days [12]. For Medicare Advantage plans administered by Aetna, a separate Medicare appeals process applies with different timelines.

Step 4: State insurance commissioner complaint. If Aetna fails to follow required timelines, a complaint to the state insurance commissioner can trigger regulatory oversight and, in some cases, accelerate resolution.

The AACE 2020 guidelines state: "For patients with osteoporosis and high fracture risk, delay of treatment due to administrative barriers represents a clinically significant risk of preventable fracture." Citing this language in the appeal letter places the clinical burden on the insurer's reviewer [4].

What Does Alendronate Actually Cost Out of Pocket?

If insurance coverage fails entirely, the out-of-pocket cost for generic alendronate is low enough that cash-pay is a viable alternative for many patients.

At CVS Pharmacy, generic alendronate 70 mg (4 tablets, one-month supply) averages approximately $15 with a GoodRx or CVS Health Savings Pass discount. Brand Fosamax carries a manufacturer list price of approximately $80 per month, which is why pursuing coverage for the brand makes financial sense mainly in cases where the generic is genuinely not tolerated [13].

GoodRx coupons, Cost Plus Drugs (Mark Cuban's pharmacy), and the Merck Patient Assistance Program are additional cost-reduction pathways for patients who remain uninsured or underinsured. Merck's Engage patient support program offers branded Fosamax at reduced cost to qualifying patients, though eligibility criteria require income verification. Patients with Aetna commercial coverage cannot stack manufacturer copay cards with commercial insurance benefits under most plan contracts, a restriction that is common across all major commercial insurers per CMS guidance on third-party payments [14].

Clinical Evidence Supporting Alendronate Coverage Decisions

Payers, including Aetna, base formulary placement and PA criteria on the clinical evidence base for a drug. Understanding that evidence helps prescribers write more persuasive PA letters.

The FIT trial (JAMA 1998, N=2,027) remains the landmark study. Alendronate 5 to 10 mg daily over 3 years reduced clinical fractures by 55% in women with prior vertebral fracture and by 36% in women without prior vertebral fracture (P<0.001 for both subgroups) [3]. A separate FIT extension, FLEX (N=1,099), found that women who continued alendronate for 10 years maintained bone density gains, while those who stopped after 5 years experienced partial reversal, supporting long-duration therapy in high-risk patients [15].

A Cochrane review (2008, updated 2011) of alendronate in postmenopausal osteoporosis (70 trials, N>12,000) confirmed statistically significant reductions in vertebral, non-vertebral, and hip fractures, with the number needed to treat for one vertebral fracture over 3 years estimated at 14 [16]. The FDA label lists the approved dosing regimens: 70 mg once weekly or 10 mg once daily for osteoporosis treatment, and 35 mg once weekly for prevention [1].

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women recommends bisphosphonates as first-line pharmacological therapy, with alendronate specifically cited given its 20-year post-marketing safety record and low cost [17]. That guideline also notes: "The risk of atypical femoral fracture with bisphosphonate use is approximately 3.2, 50 per 100,000 person-years, substantially lower than the fracture risk prevented by treatment in high-risk patients."

For glucocorticoid-induced osteoporosis, the American College of Rheumatology (ACR) 2022 guidelines recommend alendronate as a first-line agent in patients taking prednisone 2.5 mg or more per day for 3 months or longer when fracture risk is moderate to high [18]. Prescribers documenting glucocorticoid-induced osteoporosis on the PA form should reference both the ACR guideline and the patient's cumulative glucocorticoid dose.

Aetna Medicare Advantage vs. Commercial Plan Coverage

Aetna's coverage rules for alendronate differ between its commercial plans and its Medicare Advantage (MA) plans.

On Aetna Medicare Advantage plans, alendronate is covered under Part D pharmacy benefits. The formulary tier and PA criteria are governed by CMS Part D regulations, which require that each MA-PD plan cover at least two drugs in every therapeutic class. Generic alendronate appears on most Aetna Medicare Advantage formularies at Tier 1 (preferred generic), resulting in $0 to $10 copays for members in the deductible phase [19]. Brand Fosamax is less commonly covered on MA formularies because the generic is therapeutically equivalent.

The Medicare Part D Extra Help (Low Income Subsidy) program reduces cost-sharing further for eligible beneficiaries, potentially to $0 for Tier 1 generics. Patients should check their Annual Notice of Change document each fall to confirm any tier changes for the following plan year. CMS requires plans to notify members of formulary changes that affect their current medications at least 60 days before the effective date [20].

Special Populations: Who Gets Extra Scrutiny on PA?

Certain patient populations face additional PA hurdles because alendronate is not FDA-approved for all uses that clinicians sometimes prescribe.

Men with osteoporosis. Alendronate is FDA-approved for osteoporosis in men [1], but some Aetna plans apply PA criteria requiring documentation of a DXA T-score at or below -2.5 or a fragility fracture history. The International Society for Clinical Densitometry recommends DXA testing in men aged 70 and older, and in men aged 50, 69 with risk factors [21]. Including the DXA report and the relevant ISCD guideline in the PA submission typically resolves these requests quickly.

Premenopausal women. Alendronate does not carry an FDA indication for premenopausal osteoporosis, and most Aetna plans will deny PA requests for this off-label use without strong specialist documentation. The Endocrine Society notes that bisphosphonate use in premenopausal women is generally reserved for cases of secondary osteoporosis with documented severe bone loss and a clear secondary cause [17].

Patients with renal impairment. The FDA label contraindicates alendronate in patients with creatinine clearance below 35 mL/min [1]. Aetna clinical reviewers may request renal function data when reviewing PA submissions for older patients or those with documented kidney disease. Including a recent BMP or CMP with the PA packet addresses this proactively.

Checking Your Specific Aetna Plan's Coverage

Coverage details vary by plan, and no general article substitutes for checking your specific benefit documents. Here are the exact steps to confirm alendronate coverage on your Aetna plan.

1. Log in to your Aetna member portal at aetna.com and manage to the drug cost estimator tool. Enter "alendronate" and your ZIP code to see the exact tier, copay, and any PA or step therapy flags on your specific plan.
2. Call the member services number on the back of your insurance card and ask the pharmacy benefits representative: (a) what tier is alendronate 70 mg on my plan, (b) is prior authorization required for generic or brand, and (c) does step therapy apply.
3. Ask your pharmacist to run a test claim before you pick up the prescription. A rejected test claim will generate a rejection code that tells your prescriber exactly what documentation Aetna needs.
4. Request the Aetna Pharmacy Clinical Policy Bulletin relevant to alendronate. Aetna publishes these bulletins publicly at aetna.com/cpb. The bulletin number for musculoskeletal agents and bisphosphonates lists the exact PA criteria in force for the current plan year [22].

Confirming these details before the prescription is sent to the pharmacy eliminates the most common source of delay: discovering a PA requirement at the point of dispensing when the patient is already at the counter.